XRTX
XORTX Therapeutics Inc. Common Stock
stockNASDAQ
xortx therapeutics inc., a bio-pharmaceutical company, focuses on the development and commercialization of therapies to treat progressive kidney diseases worldwide. it has two lead programs, including treatments for progressive kidney disease due to diabetes, diabetic nephropathy and polycystic kidney disease. the company focuses on developing therapies for health consequences that includes pre-diabetes, diabetes, and cardiovascular disease. in addition, it develops uric acid lowering agents to treat diabetic nephropathy, hypertension, insulin resistance, metabolic syndrome, and diabetes; and xanthine oxidase inhibitors. the company has a strategic alliance with teijin pharma limited to develop tmx-049, a xanthine oxidoreductase; and a partnership with the icahn school of medicine to study the incidence of acute kidney injury and hyperuricemia in patients hospitalized with covid-19. xortx therapeutics inc. is headquartered in calgary, canada.
| Period | Price | Date | Change | Beta |
|---|---|---|---|---|
| 1W | 1.70 | 2026-10-05 | -3.53% | -16.922 |
| 1M | 2.33 | 2026-09-11 | -29.61% | -0.497 |
| 3M | 2.03 | 2026-07-13 | -19.21% | 0.694 |
| 6M | 2.21 | 2026-04-13 | -25.79% | -0.246 |
| 1Y | 4.39 | 2025-10-13 | -62.65% | 0.826 |
| 2Y | 7.65 | 2024-10-11 | -78.56% | — |
| 5Y | 141.30 | 2021-10-13 | -98.84% | 0.326 |
XORTX Therapeutics Inc. Common Stock (NASDAQ:XRTX) stock price today is $1.64, and today's volume is 303,945. XRTX is up 16.312% today. The 30 day average volume is 1.44M. XRTX market cap is $2.98M with 1.82M shares outstanding.